Wasana PrasitsuebsaiTim R. CresseyEdmund CapparelliNirun VanpraparKeswadee LapphraKulkanya ChokephaibulkitMahidol UniversityChiang Mai UniversityHarvard School of Public HealthUniversity of California, San Diego2018-06-112018-06-112012-04-01Pediatric Infectious Disease Journal. Vol.31, No.4 (2012), 389-39115320987089136682-s2.0-84858800794https://repository.li.mahidol.ac.th/handle/20.500.14594/14881We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4-11.7) years. The nevirapine area under the concentration versus time curve from 0 to12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mg.h/mL and 6.4 (3.00-13.27) mg/mL, respectively, providing adequate exposure. © 2012 by Lippincott Williams & Wilkins.Mahidol UniversityMedicineArticleSCOPUS10.1097/INF.0b013e3182401c41